Resources
EACH Coalition Submits Letter to OR PDAB on Board Policy Recommendations and Annual Report
The EACH Coalition submitted comments to the Oregon board on the proposed policy recommendations and draft annual PDAB report. The...
Read More
EACH Coalition Submits Sign-On Letter to CO PDAB on Affordability Review Rule and Policies
The EACH Coalition submitted comments to the Colorado board on the updated redline versions of the affordability rule and policy...
Read More
EACH Coalition Submits Letter to OR PDAB on UPL Plan
The EACH Coalition submitted comments to the board providing input for their planned report to the Oregon legislature on a...
Read More
EACH Coalition Submits Letters to MD PDAB on Drugs Selected for Cost Reviews
The EACH Coalition submitted letters to the MD PDAB in response to a request for input on the first 4...
Read More
EACH Coalition Submits Letter to MD PDAB on UPL Implementation Rules and Policies
The EACH Coalition submitted comments to the MD PDAB in response to requested input on COMAR 14.01.05 (Policy Review, Final...
Read More
National Network Spotlight: Rare Access Action Project
The Rare Access Action Project (RAAP) is an ad hoc coalition advocating for solutions to rare disease patient access in...
Read More
EACH Coalition Submits Letter to MD Stakeholder Council on the UPL Action Plan
The EACH Coalition submitted comments to the stakeholder council providing input on the Maryland Upper Payment Limit Action Plan ahead...
Read More
EACH Coalition Submits Letter to MD PDAB on the UPL Action Plan
The EACH Coalition submitted comments to the board providing input on the Maryland Upper Payment Limit Action Plan ahead of...
Read More
EACH Coalition Submits Letter to CO PDAB on Affordability Rule and Policy / Procedure Redlines
The EACH Coalition submitted comments to the Colorado board on the updated redline versions of the affordability rule and policy...
Read More
National Network Spotlight: Aimed Alliance Presents During October Meeting
During the EACH Coalition monthly meeting for October, Aimed Alliance provided an update on their work around PDABs and highlighted...
Read More
EACH Coalition Submits Letter to CO PDAB on Affordability Review Rule Urging for More Patient Engagement
The EACH Coalition submitted comments ahead of the Stakeholder Meeting held on September 24th urging for increased patient engagement and...
Read More
EACH Coalition Submits Letter to WA PDAB on Drug Review Process
As the Washington PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with...
Read More
EACH Coalition Submits Letter to MD PDAB on Draft UPL Plan
In response to the Maryland PDAB’s request for comments on their draft plan on Upper Payment Limits, the EACH Coalition...
Read More
EACH Coalition Submits Letter to OR PDAB on Drug Review Process
As the Oregon PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with...
Read More
EACH Issues Statement on CMS Prices for First 10 Drugs Subject to Medicare Negotiation
“The EACH Coalition is dedicated to lowering drug costs for patients; however, we are concerned that price limits have little...
Read More
PIC Launches Patient-Created Survey on Drug Affordability and Access
More and more patients are reporting difficulty getting the medications they need to maintain their health. However, in our complicated...
Read More
EACH Coalition Submits Letter to MD PDAB on Drug Reviews and UPLs
In response to the Maryland PDAB’s request for comments on their selection of six drugs for cost review, the EACH...
Read More
EACH Coalition Submits Testimony to WA PDAB on Therapeutic Alternatives
In response to the Washington PDAB’s request for input on therapeutic alternatives, the EACH Coalition submitted a testimony urging the...
Read More
EACH Coalition Submits Group Comments to CMS re: Medicare Drug Price Negotiation Guidance
As part of its ongoing effort to implement IRA changes to the Medicare Part D program, CMS issued Medicare Drug...
Read More
EACH Coalition Submits Letter to Colorado PDAB on Cosentyx and Stelara Unaffordability Decision
Following the decisions by the Colorado PDAB designating Cosentyx and Stelara as unaffordable to patients in Colorado, the EACH Coalition...
Read More
National Network Spotlight: Rare Access Action Project
The Rare Access Action Project (RAAP) is an ad hoc coalition advocating for solutions to rare disease patient access in...
Read More
National Network Spotlight: Aimed Alliance Presents During October Meeting
During the EACH Coalition monthly meeting for October, Aimed Alliance provided an update on their work around PDABs and highlighted...
Read More
Patient 101: Prescription Drug Affordability Board
States across the country are creating Prescription Drug Affordability Boards. The boards are tasked with evaluating prescription drug costs in...
Read More
Nationwide PDAB Outlook: Mapping Existing and Potential PDABs
The first PDAB was established in Maryland in 2019 and since that time, more have been created in states across...
Read More
New to PDABs? Make Sure to Get the Facts
Americans are concerned about the affordability of everything from bread to prescription medications. That’s why headlines about PDABs lowering patient...
Read More
PIC Launches Patient-Created Survey on Drug Affordability and Access
More and more patients are reporting difficulty getting the medications they need to maintain their health. However, in our complicated...
Read More
Patient 101: Prescription Drug Affordability Board
States across the country are creating Prescription Drug Affordability Boards. The boards are tasked with evaluating prescription drug costs in...
Read More
Nationwide PDAB Outlook: Mapping Existing and Potential PDABs
The first PDAB was established in Maryland in 2019 and since that time, more have been created in states across...
Read More
New to PDABs? Make Sure to Get the Facts
Americans are concerned about the affordability of everything from bread to prescription medications. That’s why headlines about PDABs lowering patient...
Read More
EACH Coalition Submits Letter to OR PDAB on Board Policy Recommendations and Annual Report
The EACH Coalition submitted comments to the Oregon board on the proposed policy recommendations and draft annual PDAB report. The...
Read More
EACH Coalition Submits Sign-On Letter to CO PDAB on Affordability Review Rule and Policies
The EACH Coalition submitted comments to the Colorado board on the updated redline versions of the affordability rule and policy...
Read More
EACH Coalition Submits Letter to OR PDAB on UPL Plan
The EACH Coalition submitted comments to the board providing input for their planned report to the Oregon legislature on a...
Read More
EACH Coalition Submits Letters to MD PDAB on Drugs Selected for Cost Reviews
The EACH Coalition submitted letters to the MD PDAB in response to a request for input on the first 4...
Read More
EACH Coalition Submits Letter to MD PDAB on UPL Implementation Rules and Policies
The EACH Coalition submitted comments to the MD PDAB in response to requested input on COMAR 14.01.05 (Policy Review, Final...
Read More
EACH Coalition Submits Letter to MD Stakeholder Council on the UPL Action Plan
The EACH Coalition submitted comments to the stakeholder council providing input on the Maryland Upper Payment Limit Action Plan ahead...
Read More
EACH Coalition Submits Letter to MD PDAB on the UPL Action Plan
The EACH Coalition submitted comments to the board providing input on the Maryland Upper Payment Limit Action Plan ahead of...
Read More
EACH Coalition Submits Letter to CO PDAB on Affordability Rule and Policy / Procedure Redlines
The EACH Coalition submitted comments to the Colorado board on the updated redline versions of the affordability rule and policy...
Read More
EACH Coalition Submits Letter to CO PDAB on Affordability Review Rule Urging for More Patient Engagement
The EACH Coalition submitted comments ahead of the Stakeholder Meeting held on September 24th urging for increased patient engagement and...
Read More
EACH Coalition Submits Letter to WA PDAB on Drug Review Process
As the Washington PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with...
Read More
EACH Coalition Submits Letter to MD PDAB on Draft UPL Plan
In response to the Maryland PDAB’s request for comments on their draft plan on Upper Payment Limits, the EACH Coalition...
Read More
EACH Coalition Submits Letter to OR PDAB on Drug Review Process
As the Oregon PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with...
Read More
EACH Coalition Submits Letter to MD PDAB on Drug Reviews and UPLs
In response to the Maryland PDAB’s request for comments on their selection of six drugs for cost review, the EACH...
Read More
EACH Coalition Submits Testimony to WA PDAB on Therapeutic Alternatives
In response to the Washington PDAB’s request for input on therapeutic alternatives, the EACH Coalition submitted a testimony urging the...
Read More
EACH Coalition Submits Group Comments to CMS re: Medicare Drug Price Negotiation Guidance
As part of its ongoing effort to implement IRA changes to the Medicare Part D program, CMS issued Medicare Drug...
Read More
EACH Coalition Submits Letter to Colorado PDAB on Cosentyx and Stelara Unaffordability Decision
Following the decisions by the Colorado PDAB designating Cosentyx and Stelara as unaffordable to patients in Colorado, the EACH Coalition...
Read More
EACH Coalition Submits Group Letter to Maryland PDAB on Therapeutic Alternatives
In response to the Maryland PDAB’s request for input on therapeutic alternatives, the EACH Coalition submitted a group letter urging...
Read More
EACH Coalition Submits Letter to Colorado PDAB on Enbrel Unaffordability Decision
Following the decision by the Colorado PDAB designating Enbrel as unaffordable to patients in Colorado, the EACH Coalition submitted comments...
Read More
EACH Issues Statement on CMS Prices for First 10 Drugs Subject to Medicare Negotiation
“The EACH Coalition is dedicated to lowering drug costs for patients; however, we are concerned that price limits have little...
Read More